cvot tirzepatide Tirzepatide CV Safety Comparable to Dulaglutide in SURPASS-CVOT | Paramesh Shamanna posted on the topic

New SURPASS-CVOT Ad Hoc Analysis: Tirzepatide outperforms dulaglutide for reducing cardiorenal risks in T2D patients : r/Zepbound

25.11

★★★★☆4.8 (126)

Key milestones of tirzepatide in the treatment of diabetes, obesity and...

27.87

★★★★★4.9 (98)

SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I

22.54

★★★★★5.0 (157)

Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function

24.37

★★★★★4.7 (84)

Effects of tirzepatide on adjudicated cardiovascular events in

29.89

★★★★★4.9 (203)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

20.23

★★★★★5.0 (176)

Manjaro* controversial amp Cardiovascular outcomes: In SURPASS-CVOT (a large CVOT in patientswith type 2 diabetes and established atherosclerotic cardiovascular disease) tirzepatide demonstrated non nferiority to dulaglutide for the 3-point major

20.95

★★★★★4.8 (132)